CDNA CAREDX INC

CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting

CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a change to its 2020 Annual Meeting of Stockholders.  Due to conditions associated with the impact of the Coronavirus pandemic (COVID-19), including restrictions on in-person gatherings, and in order to support the health and well-being of our stockholders and other meeting participants, CareDx’s 2020 Annual Meeting of Stockholders will be held in a virtual meeting format only.

The previously announced date and time of the Annual Meeting, June 17, 2020 at 10:00 a.m. Pacific Time, will not change.  There is also no change to the items of business to be addressed at the Annual Meeting, which are described in CareDx’s proxy materials as previously distributed.  As noted above, stockholders may not attend the Annual Meeting in person.  Instead, stockholders should follow the instructions provided below to attend the virtual Annual Meeting.  Broadridge Financial Solutions, Inc. will host the virtual Annual Meeting.

Stockholders are encouraged to vote their shares prior to the virtual Annual Meeting by any of the methods described in the proxy materials.  The proxy card and voting instructions form included with the previously distributed proxy materials will not be updated to reflect the change in the format of the meeting, but they may continue to be used to vote the shares on the proposals to be presented at the virtual Annual Meeting.  Stockholders who have previously voted do not need to take any further action.

Instructions to Attend the Virtual Annual Meeting

To access the virtual Annual Meeting, CareDx stockholders should go to /CDNA2020.  You can log in using one of two options: join as a “Guest” or join as a “Stockholder.” To join as a “Guest,” enter your name and email address; there will be no password.  To join as a “Stockholder,” you will be required to have a control number. If you join as a Stockholder, you can vote during the virtual Annual Meeting by following the instructions available on the meeting website.

Record Holders: Holders of record of CareDx common stock at the close of business on April 21, 2020 (i.e., shares held in the holder’s own name in the records of CareDx’s transfer agent, Computershare) can find their control number on their proxy card or Notice of Internet Availability, and enter the virtual Annual Meeting as a “Stockholder.”

Beneficial Owners: Beneficial owners of common stock of CareDx at the close of business on April 21, 2020 (i.e., shares held in the “street name” through an intermediary, such as a bank, broker or other nominee) who wish to vote their shares at the virtual Annual Meeting as a “Stockholder”, must obtain a valid proxy from the beneficial owner’s broker, bank or other agent in whose name the shares are registered.

Please note that if attendees do not have a control number, they may attend as a “Guest,” but will not have the option to vote their shares or ask questions at the virtual Annual Meeting.

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: .

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393



Investor Relations

Greg Chodaczek

646-924-1769

EN
08/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...

 PRESS RELEASE

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung...

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gim...

 PRESS RELEASE

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 o...

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents tha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch